리라글루타이드와 제2형 당뇨병에서의 심혈관 결과

Marso 등(월,)이 이 질문을 연구하였다.

www.synapsesocial.com/papers/695fc5b472b3a9f3be654075 — DOI: https://doi.org/10.1056/nejmoa1603827

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial· 2005 · 4,123 citations
2. Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation· 2010 · 640 citations
3. Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial· 2013 · 244 citations
4. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia· 2012 · 1,626 citations
5. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes· 2013 · 2,516 citations